UPDATE -- Sol-Gel Technologies to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference
25 mars 2020 10h58 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, March 25, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Reports Full Year 2019 Financial Results and Corporate Update
24 mars 2020 16h05 HE
|
Sol-Gel Technologies Ltd.
Top-line generic product revenue of $22.8 million in fiscal 2019New Drug Applications for Epsolay® and Twyneo® remain on track for the second quarter and second half 2020, respectively NESS ZIONA,...
Sol-Gel Technologies to Report Full Year 2019 Financial Results and Corporate Update
19 mars 2020 17h45 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, March 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel to Present at the Cowen 40th Annual Health Care Conference
19 févr. 2020 09h25 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing...
Sol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary Shares
14 févr. 2020 06h45 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks
13 févr. 2020 16h05 HE
|
Sol-Gel Technologies Ltd.
Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea Results pave the way for NDA submission in the second quarter of...
Sol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020
05 févr. 2020 07h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
21 janv. 2020 16h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) today announced the presentation of results from the Company’s Phase 3...
Sol-Gel Hosts Investor Call to Discuss Positive Results from Twyneo® Phase 3 Program in Acne Vulgaris
08 janv. 2020 07h00 HE
|
Sol-Gel Technologies Ltd.
Conference call with Sol-Gel management and U.S. key opinion leader today at 8:00 a.m. Eastern time NESS ZIONA, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL)...
Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)
02 janv. 2020 07h30 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel,...